Advancing the repurposing of ivermectin for malaria

Overall, LiGHT was a well designed trial that demonstrates selective laser trabeculoplasty's acceptable safety and efficacy. Based on UK standards, the 3-year cost savings for giving selective laser trabeculoplasty first appear to be substantial. In the USA, where the price of medications is higher than in some single-payer systems, the cost savings might be even greater. In an ageing population, as glaucoma is becoming more prevalent and medical costs are escalating, the LiGHT trial provides evidentiary support for ophthalmologists to consider selective laser trabeculoplasty as first-line treatment for ocular hypertension and open-angle glaucoma.

Jonathan W Young, *Joseph Caprioli
Stein Eye Institute, University of California–Los Angeles, CA 90095, USA
caprioli@sei.ucla.edu

We declare no competing interests.

Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.


There is ever-increasing anticipation for the potential of mass drug administration of endectocides (also known as systemic insecticides) to reduce malaria transmission, with ivermectin emerging as the most likely first-in-class endectocide.1 More than half of the 46 papers published on this subject in the past decade appeared in the past 2 years. 23 projects are registered in the MESA Track database, of which seven are active today; and, more importantly, trial mapping by the Malaria Ivermectin Roadmap2 shows that abundant new evidence on the topic will be available by 2020.

Why is there so much interest in repurposing ivermectin? After achieving remarkable advances from 2000 to 2015, the global fight against malaria has stalled.3 Beyond funding and access gaps, residual transmission driven by mosquito behavioural adaptations that allow avoidance of home-based insecticides—has become a key liability for vector control, and challenges achievement of the global goals set forth by WHO.4

Ivermectin lays the path for a whole new concept: drug-based vector control.5 6 Ivermectin, or indeed any effective endectocide, could be administered to eligible members of the at-risk community as a complementary tool for vector control. It could be administered alone or in combination with partner drugs to allow for integrated management of malaria or neglected tropical diseases, directly responding to residual transmission by targeting malaria and some lymphatic filariasis vectors, regardless of their feeding behaviour.7 8

In The Lancet, Brian Foy and colleagues9 report the results of the RIMDAMAL trial, which enrolled participants from eight village clusters in a high-transmission area in southwestern Burkina Faso. Eligible village residents in the control and intervention groups received a single 150–200 μg/kg dose of ivermectin plus 400 mg of albendazole, but those in the intervention group received five additional 3-weekly doses of ivermectin alone, with mass drug administration coverage of 70–75% across the 18-week intervention period. The active case detection cohort comprised children aged 5 years
or younger who were living in these villages. These children were visited three times every 2 weeks by a nurse who tested them for malaria, assessed symptoms, and provided treatment, if needed, allowing for monitoring of malaria incidence in this key age group. The primary outcome was cumulative malaria incidence (adjusted for sex and clustering), which was reduced in the intervention group (648 episodes among 327 children; 2·00 episodes per child) compared with the control group (647 episodes among 263 children; 2·49 episodes per child; risk ratio 0·81 [95% CI 0·72–0·90]; risk difference –0·49 [–0·79 to –0·21]; p=0·0009).

Although the sample size was small and the regimen chosen for this trial (six doses over an 18-week period) might not have been optimal for implementation, these results provide the first evidence of an effect of mass ivermectin administration that goes beyond mosquito mortality, showing a measurable reduction in malaria incidence in children aged 5 years or younger, thereby demonstrating the concept of community effects. This trial continues to build the evidence base and, thus, increase interest in the repurposing of an existing drug that could help bridge to a more effective malaria strategy at a time when malaria progress is threatened, as shown by the increase in cases globally.

Ongoing or soon-to-start trials will assess the efficacy and safety of the new malaria indication of ivermectin with two different dosing regimens: either three consecutive daily doses of 300 μg/kg, as identified by the IVERMAL dose-ranging study, which showed a good compromise between safety and the effects on mosquitoes; or a single-dose regimen of 400 μg/kg, currently used for control of lymphatic filariasis. Pharmacokinetic and modelling data support the evaluation of both regimens for the malaria indication. Ivermectin will be tested as identified by the IVERMAL dose-ranging study,